ライフサイエンスコーパス: pituitary tumor

1 anel in the diagnosis of various subtypes of pituitary tumors.

2 sible therapeutic target in the treatment of pituitary tumors.

3 Gal-3 in the development and progression of pituitary tumors.

4 us sinus fistulae, parasellar syndromes, and pituitary tumors.

5 posed as novel oral medications for managing pituitary tumors.

6 rmone receptor PPAR-gamma in all of 39 human pituitary tumors.

7 role for selective antiestrogens in treating pituitary tumors.

8 -378 RB-producing ES cells failed to develop pituitary tumors.

9 adenomas compared with that in nonsecreting pituitary tumors.

10 tiation and increases the susceptibility for pituitary tumors.

11 of human anterior pituitary cells and human pituitary tumors.

12 al cell proliferation, and susceptibility to pituitary tumors.

13 ce and increased penetrance of hGHRH-induced pituitary tumors.

14 pressed in malignant human cell lines and in pituitary tumors.

15 the recently proposed genetic treatments for pituitary tumors.

16 gnostic and potential therapeutic targets in pituitary tumors.

17 fects in the Rb gene are not common in human pituitary tumors.

18 44) rat induces growth of large, hemorrhagic pituitary tumors.

19 product occurs at a high frequency in human pituitary tumors.

20 tiple parathyroid, pancreatic, duodenal, and pituitary tumors.

21 nostic yield for localizing small functional pituitary tumors.

22 period, excluding all craniopharyngioma and pituitary tumors.

23 e utility of this tracer in the detection of pituitary tumors.

24 ous role for these cells in the induction of pituitary tumors.

25 tumorigenesis in Rb1-deficient prostate and pituitary tumors.

26 CTH) and adrenal steroid secretion caused by pituitary tumors.

27 potential to improve care for patients with pituitary tumors.

28 Gli function may contribute to these common pituitary tumors.

29 anding mechanisms underlying uniquely benign pituitary tumors.

30 was significantly reduced due to aggressive pituitary tumors.

31 itary adenomas (NFPAs) are the most frequent pituitary tumors.

32 expressed in a specific cell-type manner in pituitary tumors.

33 statin ligand design to treat ACTH-secreting pituitary tumors.

34 Among pituitary tumors, 30% (7/23), mainly in follicle-stimula

35 transforming gene), a gene overexpressed in pituitary tumors [9].

36 ter, white matter, gliomas, meningiomas, and pituitary tumors, allowing their ready discrimination by

37 nderstand variance in practice management of pituitary tumors amongst neurosurgical centers.

38 l pituitaries; however, in a small number of pituitary tumors analysed, 11 beta-HSD2 was readily demo

39 dentified a miRNA signature for GH-producing pituitary tumors and found that miR-26b and miR-128 regu

40 of mRNA for 11 beta-HSD1 and 2 in 105 human pituitary tumors and have performed enzyme expression an

41 types of normal anterior pituitary cells and pituitary tumors and in other neuroendocrine cells and t

42 ed deletion of p18(INK4c) causes spontaneous pituitary tumors and lymphoma late in life.

43 A high penetrance of pituitary tumors and medullar carcinoma of the thyroid i

44 chanism of silencing of the p27 gene in some pituitary tumors and possibly in other types of neoplasm

45 nations to achieve biochemical remission for pituitary tumors and reduce tumor size.

46 review current research in the treatment of pituitary tumors and summarize emerging medical, surgica

47 including four classes: glioma, meningioma, pituitary tumor, and healthy, on a dataset containing 32

48 ads to an overall increase in animal growth, pituitary tumors, and hyperplasia of hematopoietic organ

49 PTTG is abundantly expressed in human pituitary tumors, and in 23 of 26 GH-producing pituitary

50 total number of reproductive system tumors, pituitary tumors, and metastases was increased in the of

51 ent therapy can generate menin expression in pituitary tumors, and significantly reduce tumor cell pr

52 Pituitary tumors are among the most common human neoplas

53 drenocorticotrophic hormone (ACTH)-secreting pituitary tumors are associated with high morbidity due

54 dels of these neoplasms simply do not exist: pituitary tumors are common in rodents, but their histol

55 Pituitary tumors are commonly encountered in clinical pr

56 Pituitary tumors are commonly encountered, and result fr

57 Growth hormone-secreting (GH-secreting) pituitary tumors are driven by oncogenes that induce cAM

58 Pituitary tumors are frequently associated with mutation

59 essive, young-onset growth hormone-secreting pituitary tumors are not fully understood.

60 tary tumors, the effects of EGF signaling on pituitary tumors are not known.

61 Pituitary tumors are often detected only after death or

62 Although many pituitary tumors are successfully resected, functional a

63 ain diseases, namely glioma, meningioma, and pituitary tumor, are chosen as abnormal brains, and the

64 hown to significantly reduce the severity of pituitary tumors arising in Rb1(+/-) animals by enhancin

65 o investigate the expression of p16 in human pituitary tumors as an indirect mechanism of Rb inactiva

66 rtance in the processing of pro-CCK in mouse pituitary tumor AtT-20 cells.

67 was taken up and metabolized by a culture of pituitary tumor (AtT-20) cells.

68 crucial role during development of p27(-/-) pituitary tumors because loss of one copy of Sox2 impair

69 DNA analysis of a human pituitary tumor, breast carcinoma cell lines, and thyroi

70 beta-catenin in Sox2(+) cells gives rise to pituitary tumors, but, unexpectedly, the tumor mass is n

71 , approximately 50% of the animals developed pituitary tumors by 1 year of age.

72 cate that the suppression of pars intermedia pituitary tumors by p27(Kip1) is cell-autonomous and doe

73 stioned the mechanism of Gal-3 expression in pituitary tumors, by using methylation-specific PCR and

74 Small functional pituitary tumors can cause severely disabling symptoms a

75 Pituitary tumors cause considerable morbidity due to loc

76 h levels of aberrant expression of GPR101 in pituitary tumors caused by X-LAG.

77 identified that miR-26b and miR-128 affected pituitary tumor cell behavior through regulation of thei

78 genesis we treated primary rat pituitary and pituitary tumor cell cultures with recombinant FGF-4 and

79 These data were also replicated in a pituitary tumor cell line carrying the most common PRKAR

80 estrogen receptor-alpha (mERalpha) in a rat pituitary tumor cell line, GH3/B6/F10.

81 he expression of p27 gene products in NP and pituitary tumor cell lines.

82 tases in cell-free membrane patches from rat pituitary tumor cells (GH(4)C(1)).

83 5'-triiodothyronine (reverse T3, rT3) in rat pituitary tumor cells (GH4C1).

84 hibits the growth and DNA synthesis of mouse pituitary tumor cells and human choriocarcinoma cells.

85 ETS-2 repressor factor (ERF) is expressed in pituitary tumor cells and that overexpression of recombi

86 (p27) protein in rat GH3 and mouse GHRH-CL1 pituitary tumor cells compared with normal pituitary (NP

87 aneuploid GH-secreting cells, and GH(3) rat pituitary tumor cells overexpressing PTTG also exhibited

88 d phosphorylation in GH-R2 cells, a clone of pituitary tumor cells overexpressing this receptor.

89 Expression of Id2 by pituitary tumor cells promotes growth and angiogenesis b

90 enesis and/or proliferation, and 3) cultured pituitary tumor cells respond to TGF-beta1 and PKC inhib

91 ctin promoter to dopamine was examined using pituitary tumor cells stably expressing dopamine D2 rece

92 e cell cycle and apoptotic response of these pituitary tumor cells to the dopamine analog bromocripti

93 ta-HCH occurs in estrogen-responsive GH3 rat pituitary tumor cells transfected with a luciferase repo

94 nsforming gene (PTTG1) was isolated from rat pituitary tumor cells, and subsequently identified as a

95 rat somatolactotroph, and murine gonadotroph pituitary tumor cells, and suppressed in vitro hormone s

96 ts adrenocorticotropin (ACTH) secretion from pituitary tumor cells.

97 ls with a mesenchymal phenotype evolved from pituitary tumor cells.

98 prolactin synthesis was assessed in GH3 rat pituitary tumor cells.

99 colony formation ability and invasiveness of pituitary tumor cells.

100 EN expression levels and AKT activity in the pituitary tumor cells.

101 esponds negatively to insulin in transfected pituitary tumor cells.

102 adrenocorticotropic hormone-secreting AtT20 pituitary tumor cells.

103 ing and functional actions in GH3/B6/F10 rat pituitary tumor cells.

104 cholecystokinin gene in transfected GH3 (rat pituitary tumor) cells.

105 nally discovered in a subpopulation of human pituitary tumors characterized by their invasive phenoty

106 early in adulthood when they develop lethal pituitary tumors composed solely of Rb(-/-) cells.

107 Antiestrogen treatment of primary human pituitary tumor cultures reduced PTTG expression approxi

108 fe-threatening disorder attributed to excess pituitary tumor-derived adrenocorticotrophic hormone (AC

109 e PAs and in the (nonfunctioning) HP75 human pituitary tumor-derived cell line treated with phorbol-1

110 A pituitary tumor-derived transforming gene (PTTG) has bee

111 Pituitary tumors develop at a high frequency in retinobl

112 Pituitary tumors develop in about one-quarter of the pop

113 tary cell proliferation rates, and rescue of pituitary tumor development in Rb(+/-) mice.

114 ctrometry imaging (MSI) for the detection of pituitary tumors during surgery.

115 oci reside on chromosome 6 [Estrogen-induced pituitary tumor (Ept)1], chromosome 3 (Ept2 and Ept6), c

116 cognized that most clinically nonfunctioning pituitary tumors express gonadotropin hormones or their

117 Overall, pituitary tumors expressed lower levels of 11 beta-HSDl

118 near-real-time detection and delineation of pituitary tumors for intraoperative surgical decision-ma

119 ulating the PTEN-AKT pathway in GH-producing pituitary tumor formation in the context of hyperplasia

120 We have identified a 17-miRNA signature of pituitary tumors formed in the background of hyperplasia

121 Intense molecular studies of sporadic pituitary tumors from patients with negative family hist

122 2 in initiation, growth, and angiogenesis of pituitary tumors from Rb(+/-) mice.

123 he role of p185(her2/neu)/ErbB3 signaling in pituitary tumor function, we examined these receptors in

124 ting an autocrine effect of pancreastatin on pituitary tumor function.

125 on therapy and stereotactic radiosurgery for pituitary tumors gains more widespread use, long-term da

126 e element (TRE) gene, F2-TRE-TK-CAT, both in pituitary tumor (GC) cells.

127 K+ (I(K)) and Ca++ currents in rat anterior pituitary tumor (GH3) cells were analyzed by using a who

128 and circulating sex steroid hormones promote pituitary tumor growth and expansion into large invasive

129 s by 88%, and attenuated prolactin-secreting pituitary tumor growth by 41% in rats.

130 Aneuploid pituitary cell p21 may constrain pituitary tumor growth, thus accounting for the very low

131 Management of pituitary tumors has improved in the past decade since t

132 Pituitary tumors in 55 Men1(+/-) female mice received a

133 land and induce development of PRL-producing pituitary tumors in certain inbred rat strains but not o

134 We found that the development of pituitary tumors in Rb+/- mice correlated with a reducti

135 orm aggressive growth-hormone (GH)-producing pituitary tumors in the background of hyperplasia caused

136 T) PET/MRI for detection of small functional pituitary tumors in these patients.

137 i-estrogens reduced PTTG expression in human pituitary tumors in vitro and suppressed experimental tu

138 pression of sigma-1 receptors in spontaneous pituitary tumors is detected as an increase in uptake an

139 iagnosis of various histological subtypes of pituitary tumors is made using serum based hormone panel

140 MP-dependent protein kinase pathway in human pituitary tumors; it also reviews briefly other pathways

141 cretion and ablation or stabilization of the pituitary tumor mass lead to improved comorbidities and

142 ty of therapeutic radiation in patients with pituitary tumor, medulloblastoma, and arteriovenous malf

143 e drugs are introduced for the management of pituitary tumors, more patients with hormone-secreting a

144 liomas (n = 158), meningiomas (n = 111), and pituitary tumors (n = 154) from 58 patients.

145 Spontaneous pituitary tumors occur in rats over 1 y of age.

146 corticotropin excess is produced by a benign pituitary tumor, occurs in approximately 60% to 70% of p

147 eclinical evaluation of MEN1 gene therapy in pituitary tumors of Men1(+/-) mice, using a recombinant

148 These symptoms were not associated with pituitary tumors or multiple endocrine neoplasia but wer

149 Western blotting analysis indicated that pituitary tumors overexpressed sigma-1 receptors.

150 ) vs. 30% of Rb(+/-)Pttg(-/-) mice developed pituitary tumors, P < 0.001).

151 racrine growth factor-mediated mechanism for pituitary tumor pathogenesis and potentially other estro

152 pituitary carcinomas that may contribute to pituitary tumor pathogenesis and/or proliferation, and 3

153 f surgically resected tumors from forty five pituitary tumor patients [gonadotropic (LH/FSH-secreting

154 d have therapeutic potential in GH-producing pituitary tumor patients.

155 Whereas thymic lymphomas or pituitary tumors predominate in mice lacking p53 or Ink4

156 undetectable levels of p16 mRNA in 13 of 14 pituitary tumors relative to 5 normal pituitary specimen

157 The genetic causes of common pituitary tumors remain for the most part unknown; progr

158 All patients with pituitary tumors require endocrine evaluation for hormon

159 patients initially cured by transsphenoidal pituitary tumor resection.

160 Evaluation of pituitary tumors revealed that STAT3 expression was enha

161 Pituitary tumors showed up as bright hot spots in the sc

162 expressed in all of six human ACTH-secreting pituitary tumors studied.

163 the brain and thyroid tissue of animals with pituitary tumors than in healthy rats.

164 ormone (TSH)-secreting tumors (TSH-omas) are pituitary tumors that constitutively secrete TSH.

165 E2F3 loss suppresses the development of the pituitary tumors that normally account for the death of

166 by aggressive growth hormone (GH)-secreting pituitary tumors that occur in early childhood.

167 rbB receptor family members are expressed in pituitary tumors, the effects of EGF signaling on pituit

168 The genetic etiology of most pituitary tumors, therefore, remains unknown.

169 Our human pituitary tumor transcriptome data revealed the "epithel

170 Pituitary tumor transforming gene (PTTG) binding factor

171 Pituitary tumor transforming gene (Pttg) deletion result

172 The product of the pituitary tumor transforming gene (PTTG) exhibits in vit

173 ly, we cloned and sequenced cDNA of a potent pituitary tumor transforming gene (PTTG) from human test

174 The rat pituitary tumor transforming gene (PTTG) genomic structu

175 The pituitary tumor transforming gene (PTTG) has been identi

176 Pituitary tumor transforming gene (PTTG) is a newly iden

177 Pituitary tumor transforming gene (PTTG) is a well-studi

178 Pituitary tumor transforming gene (PTTG), also known as

179 The mammalian securin, pituitary tumor transforming gene (PTTG), regulates sist

180 transgenic zebrafish with overexpression of pituitary tumor transforming gene (PTTG/securin) targete

181 The pituitary tumor transforming gene (PTTG1) is a recently

182 Pituitary tumor transforming gene (PTTG1) was isolated f

183 Recently it was found that pituitary tumor transforming gene (PTTG; also called Pds

184 Pituitary tumor transforming gene 1 (Pttg1) encodes the

185 Pituitary tumor transforming gene 1 (PTTG1), a transform

186 n was also independently identified as PTTG (pituitary tumor transforming gene), a gene overexpressed

187 The pituitary tumor transforming gene, PTTG, is abundantly e

188 Overexpression of pituitary tumor-transforming 1 (PTTG1) is associated wit

189 Human pituitary tumor-transforming 1 (PTTG1)/securin is a puta

190 Pituitary tumor-transforming gene (Pttg) deletion result

191 Pituitary tumor-transforming gene (PTTG) encodes a prote

192 Pituitary tumor-transforming gene (PTTG) is a recently c

193 Pituitary tumor-transforming gene (PTTG) is a recently c

194 Pituitary tumor-transforming gene (PTTG) is a recently c

195 Pituitary tumor-transforming gene (PTTG), the index mamm

196 identical to the product of the gene called pituitary tumor-transforming gene (PTTG), which is overe

197 revealed that known tumor promoters such as pituitary tumor-transforming gene were activated and tum

198 It is also known as the product of the human pituitary tumor-transforming gene, pttg, a proto-oncogen

199 brain tumors-such as glioma, meningioma, and pituitary tumors-using the U-Net architecture applied to

200 y proliferation to study the pathogenesis of pituitary tumors, we crossed the glycoprotein hormone al

201 s system lymphoma without residual tumor and pituitary tumors were reported recently.

202 H4C1 cells, a clonal line derived from a rat pituitary tumor, were stably transfected with the gene e

203 16 gene product was undetectable in 25 human pituitary tumors, whereas high levels of p16 could be de

204 Prolactinomas are the most frequent type of pituitary tumors, which represent 10-20% of all intracra

205 Rb1(+/-) mice develop pituitary tumors with full penetrance and the tumors are

206 ice heterozygous for the Rb mutation develop pituitary tumors, with about 20% arising from the AL.